Search

Displaying results 2711 - 2720 of 10000 in total
  1. Drug

    Metenkefalin

    go.drugbank.com/drugs/DB12668
    Investigational

    [A203210] Metenkefalin, along with [tridecactide], are under investigation as an immunomodulatory therapy for moderate to severe COVID-19.[L13874,L13877] … Metenkefalin is an endogenous opioid and beta-endorphin.[A203225] It has been shown to reduce chromosomal abberations in patients with multiple sclerosis.

  2. Drug

    Iodixanol

    go.drugbank.com/drugs/DB01249
    Approved

    Iodixanol is a nonionic hydrophilic compound commonly used as a contrast agent during coronary angiography, particularly in individuals with renal dysfunction, as it is believed to be less toxic to the

    Categories: Compounds used in a research, industrial, or household settingProducts: VISIPAQUE 270 MG/ML IA IV İNTRATEKAL ENJEKSİYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 50 ML, VISIPAQUE 270 MG/ML IA IV İNTRATEKAL ENJEKSİYON İÇİN ÇÖZELTİ İÇEREN FLAKON, 100 ML
  3. Drug

    Selexipag

    go.drugbank.com/drugs/DB11362
    ApprovedInvestigational

    PAH is a relatively rare disease with usually a poor prognosis requiring more treatment options to prolong long-term outcomes. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  4. Drug

    Plerixafor

    go.drugbank.com/drugs/DB06809
    ApprovedInvestigational

    Plerixafor is a small-molecule inhibitor of C-X-C chemokine receptor type 4 (CXCR4) that acts as a hematopoietic stem cell mobilizer. … [A7118,L45678] As an inhibitor of CXCR4, plerixafor blocks the binding of its ligand, stromal cell-derived factor-1-alpha (SDF-1α).

  5. Drug

    Fosdenopterin

    go.drugbank.com/drugs/DB16628
    Approved

    [A230088] Signs and symptoms begin shortly after birth and are caused by a build-up of toxic sulfites resulting from a lack of SOX activity. … In 2009 a recombinant, E. coli-produced cPMP was granted orphan drug designation by the FDA, becoming the first therapeutic option for patients with MoCD type A.

  6. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  7. Drug

    R1295

    go.drugbank.com/drugs/DB05122
    Experimental

    R1295 is an integrin antagonist currently in clinical trials for the treatment of rheumatoid arthritis. … Integrins are associated to the pathology seen in some of the autoimmune diseases such as rheumatoid arthritis.

  8. Drug

    Thiethylperazine

    go.drugbank.com/drugs/DB00372
    ApprovedInvestigationalWithdrawn

    A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins.

  9. Drug

    Phthalylsulfathiazole

    go.drugbank.com/drugs/DB13248
    Approved

    Phthalylsulfathiazole is a broad spectrum antibiotic which is part of the drug class, sulfonamides. It was used as an antibiotic for bowel surgery, and for infections of the colon [A175006].

  10. Drug

    Aficamten

    go.drugbank.com/drugs/DB18490
    ApprovedInvestigational

    Aficamten is a cardiac myosin inhibitor.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Substrates